“Death in Hamburg” by @RichardEvans36. A book written in 1987for our COVID age. The title, a reference to Thomas Mann's Death in Venice, this is a review of one of the best books I've ever read. 5/5 stars. 🧵 https://t.co/qjJ1rDs5BB
AI is advancing rapidly, giving big corporations unprecedented opportunities to collect and use information about our personal identity and spending habits. Our consumer protections must keep pace to ensure AI works for us, not against us. https://t.co/jbh5KiaL2D
There still in no approved or highly effective treatment for postural orthostatic tachycardia syndrome (POTS), which can be debilitating.
Now there's hope with very encouraging results of a Phase 2 randomized trial: an antibody vs natriuretic peptide receptor 1 (NRP-1)
https://t.co/mts2NlvAYk
🚨 My new paper on small fiber #neuropathy in NONPAINFUL conditions is published. Neuropathy is traditionally defined by neuropathic (tingling, numbness, burning, shooting) pain, but there are neurologic and non-neurologic conditions where objective findings of small fiber neuropathy are highly prevalent despite the pain being absent or minimal. I outline comprehensive treatment options for small fiber neuropathy with both evidence-based and emerging therapies in the Table. 🧠
https://t.co/YBTEFiTWyl
In new study, we show that SARS-CoV-2 has evolved decreased inherent antigenicity in humans, as quantified by a ~3-fold decrease in the number of naïve human B cells that can bind the spike RBD.
https://t.co/OabX5bSYwp
SARS-CoV-2 community spread in Aotearoa NZ began with Omicron in January 2022 (the 2021-22 data point on this chart).
ED presentations jumped up, and they kept increasing (even though the SARS-2 waves got smaller after mid-22).
This is a growing burden of SARS-2 chronic harm.
"Korea makes COVID-19 vaccination part of routine national immunization program"
KDCA says COVID-19 continues producing variants that can evade immunity, while people 65+ account for 63% of hospitalisations. It is shifting to routine vaccination to protect high-risk groups.
A slightly more personal post than usual.
I’ve always believed that scientific disagreement can be discussed without turning into insults, mockery or personal attacks.
Over the last few days, I’ve realised that this seems to have become much harder in some parts of this community.
And honestly, I find that sad.
(1/9) 🧵
The @ISLCPAIS conference website was hacked more than twice including during the event. We received massive amounts of criticism online, and more than once @miketweetchap received threats at his home address, simply for trying to bring people together.
Michael, you did nothing wrong.
You poured your heart and soul into this conference, while carrying the additional reality of being a Long Covid patient yourself. I saw how much work, energy and care you put into making this happen, and I honestly think what you accomplished was tremendous.
Those of us working in this field are fighting on so many fronts. We are fighting #COVID and #LongCovid denial and dismissal, while also having to deal with radical voices within our own community attacking the very people who are trying to move the field forward. It is exhausting.
But for the last days, we saw what can happen when people come together despite all of that. Scientists, physicians and patient advocates in the same room, sharing ideas, building collaborations and trying to find better answers for patients.
So please don't let the attacks make you question why you did this. You did it because you care. And you created something that brought people together when we desperately need more of that.
I’m incredibly grateful to be part of this and I hope you take a moment to be proud of what you accomplished. ❤️
The 2026 Amsterdam ISLC-PAIS Conference Abstract Book is now officially online. The Abstract Book is exclusively available to registered in-person attendees. Please log in and visit the Your Access section in the attendee portal to access it.
On behalf of our chair @RobWust we thank all researchers, clinicians, healthcare professionals and experts by experience who submitted their work on Long COVID, ME/CFS and Post-Acute Infection Syndromes (PAIS).
I do believe science can unite safely & accomplish 5 months worth of time into 4 days. Whatever it takes to get this subject matter to the next generation of scientists & doctors who have been encouraged to study #LongCovid.
Ideas are priceless.
#ISLCPAIS2026 abstract review.
My thoughts on abstract 2
One of my fav studies which basically replicates @VirusesImmunity bigger studies in transfer of IgG from
patients with #longcovid to mice.
This study provides further evidence for an immune-mediated mechanism of pain in Long COVID, showing that patient-derived IgG targets peripheral sensory neurons in vivo and ex vivo. These findings strengthen the rationale for testing immunomodulatory approaches such as IVIG in carefully designed clinical trials.
Importantly, funding strategies should not focus exclusively on viral persistence: the growing evidence for pathogenic autoantibodies and immune-mediated neuronal dysfunction makes immunomodulation a parallel, high-priority therapeutic avenue that warrants properly powered clinical trials. I’m surprised this is still not on the priority list
Thank you so much to everyone for the kind messages and support 🥹! Happy to share that I won the 2026 Young Investigator award @ISLC_PAIS and also met the amazing Dr. Funmi Okunola
@longcovidanswer
We will keep fighting and we won't give up! 💪 #LongCovid#MECFS#PAIS
ISLC-PAIS 2026 Young Investigator Award
Huge congratulations to Dr. @DaniBeckman on receiving the ISLC-PAIS 2026 Young Investigator Award, recognition of her outstanding research into Long COVID and post-acute infection syndromes.
#ISLCPAIS#LongCOVID#PAIS#MEcfs
Important review about #POTS from my colleague @satish_r_raj, who is part of our @ISLC_PAIS society and presenting in our meeting this Friday.
#LongCovid
We’ve been building this society together for years and today we finally meet in Amsterdam! 🧡
The inaugural ISLC-PAIS Conference starts today with 4 days of science, collaboration and new connections to fight for #LongCOVID and #PAIS.
Welcome to #ISLCPAIS2026! 🔬
@ISLCPAIS
Hello, Amsterdam! 🇳🇱🧡
So excited to be here for the first ISLC-PAIS Conference and to finally see so many colleagues, collaborators & friends in person!
Four days of #LongCOVID and #PAIS science, discussions and new ideas ahead. 🧠🔬
#ISLCPAIS2026
Only one week to go until the 2026 Amsterdam ISLC-PAIS Conference brings together more than 300 clinicians, scientists, early-career researchers and patient advocates, all committed to advancing our understanding of Long COVID and other Post-Acute Infection Syndromes.
With more than 100 scientific sessions, the conference will cover the latest research, clinical insights and developments across the field.
To make the key takeaways accessible beyond the conference itself, we are organising the Patient Recap Livestream Session. A dedicated session that translates the most relevant conference insights into clear and accessible information for patients.
https://t.co/xCL1M3wQdw